On April 13, the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration recommended that all hospitals, clinics, and other providers sites, including Indian Health Service (IHS) and Tribal health facilities and clinics, pause the use of the Johnson & Johnson’s Janssen COVID-19 vaccine due to reports of adverse events. In the United States, there have been six reported cases of a rare and severe type of blood clot known as cerebral venous sinus thrombosis (CVST) along with low levels of blood platelets (thrombocytopenia). These cases have only been observed in women between ages 18 and 48 with symptoms beginning six to 13 days after receiving the J&J/Janssen vaccination.